Patients hospitalized for severe COVID-19 and receiving therapeutic doses of LMWH should be tested for antiphospholipid antibodies [aPLs]: anticardiolipin [aCL] IgG/IgM, anti-β2-glycoproteinI [anti-β2GPI] IgG/IgM, and antiprothrombin-phosphatidilserine antibody [aPS/PT] IgG/IgM at least twice: when admitted and when discharged. The gene discussed is APOH; the disease is COVID-19.